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A B S T R A C T
Purpose
To determine whether germ-line variations in BRCA1 affect outcome in non–small-cell lung cancer
(NSCLC) patients treated with platinum combination chemotherapy.
Patients and Methods
We evaluated the associations of four tagging BRCA1 polymorphisms and their haplotypes with
treatment outcome in 300 NSCLC patients at stages IIIA (16%), IIIB (31%), and IV (53%).
Results
The median age was 63 years (range, 28 to 89 years). Histologically, 139 (46.3%) of the patients
had squamous cell carcinomas and 137 (45.7%) had adenocarcinomas. Patient median survival
time (MST) was 13.0 months. We observed no significant association between any of the tagging
polymorphisms [S1613G, IVS13-1893 (AC), IVS12-1207 (CT), and IVS12112 (CA)] and
overall survival. Of the five haplotypes evaluated (AACC, AACA, GCTC, GATC, and AATC), the
survival of patients with two copies of the AACC (wild-type) haplotype was significantly shorter
than that of patients with zero to one copies (MST, 8.47 v 14.57 months; log-rank P .0066), even
after adjustment for body weight loss, performance status, stage, second-line treatment, and
radiation therapy (hazard ratio  2.097; 95% CI, 1.339 to 3.284). The survival of patients with
squamous cell carcinoma and two copies was significantly shorter than that of other patients with
squamous cell carcinoma (MST, 6.8 v 15.3 months; log-rank P 3.6 105), whereas differences
in survival between the two adenocarcinoma groups was not significant (log-rank P  .677).
Conclusion
These findings suggest that the AACC haplotype of the BRCA1 gene is an important prognostic
marker in NSCLC patients treated with platinum combination chemotherapy.
J Clin Oncol 26:5972-5979. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Lung cancer is the most common cause of cancer-
related death in many countries, but the survival of
patients with non–small-cell lung cancer (NSCLC)
has slowly been improving; now 15% of NSCLC
patients survive for 5 years.1
Despite the introduction of new drugs target-
ing specific molecules,2-4 cytotoxic chemotherapy is
still the mainstay treatment for advanced NSCLC, in
which platinum has an essential role as one part of
the doublet.5
Effective lung cancer pharmacogenomics relies
on identifying NSCLC patients who may benefit
from DNA-damaging agents, such as platinum.
Since individual variations in DNA repair capacity
influence the efficiency of DNA-damaging agents,
DNA repair pathway genes have generated great
interest as potential biomarkers. Accordingly,
genes such as ERCC1, RRM1, ERCC2, and
XRCC1, which are involved in DNA repair, have
been focused on potential biomarkers to predict
the effects of platinum-based chemotherapy in
NSCLC patients.6-9
BRCA1 also plays a central role in DNA repair
via transcription-coupled nucleotide excision re-
pair.10 BRCA1 originally described in terms of its
involvement in other repair processes, including
homologous recombination repair, nonhomolo-
gous end joining, and mismatch repair, as well as
in the regulation of mitotic spindle assembly.11-13
Recent study has identified differential BRCA1 ex-
pression as a reliable predictive/prognostic marker
for platinum-based neoadjuvant chemotherapy in
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NSCLC patients.14 However, germ-line variations inBRCA1have not
been examined in lung cancer patients.
Therefore, we assessed the association between tagging single-
nucleotide polymorphisms (tSNPs) and haplotypes of the BRCA1
gene and outcome in NSCLC patients treated with platinum com-
bination chemotherapy.
METHODS
Selection of Study Population and Acquisition of
Clinical Information
The Lung Cancer Cohort of Inha University Hospital (Incheon, South
Korea) has constructed a database system that includes clinical information
and matched peripheral-blood DNA. The clinical information was prospec-
tively obtained by a well-trained research nurse, who interviewed all lung
cancer patients at the time of diagnosis. Information regarding treatment,
tumor response, follow-up, and survival, as well as smoking habits, Eastern
Cooperative Oncology Group (ECOG) performance status, and weight loss,
was collected from the cohort using uniform data sheets. To increase the
quality of the information, a physician (J.S.R.) and a research nurse (H.J.K.)
conducted biweekly reviews of the electronic charts and the results of radio-
logic examinations or laboratory studies for each patient. If a patient was
transferred to a primary or secondary hospital, or if a patient left our hospital to
remain at home for conservative or terminal care, we contacted the patient or
relatives by telephone or mail to ascertain his or her current status.
From more than 1,000 NSCLC patients diagnosed between March 2000
and May 2006, we chose 300 patients with advanced-stage disease who were
treated with more than two cycles of platinum-based chemotherapy as a
first-line treatment, who underwent full follow-up at our hospital, and whose
peripheral-blood lymphocytes were available for analysis.
The 300 consecutive NSCLC patients chosen gave their written informed
consent and agreed to the purposes of the study. This study was approved by
the Institutional Review Board of Inha University Hospital.
Selection of Tagging Polymorphisms
TheBRCA1gene spans approximately 81.2 kb and contains 24 exons. All
polymorphisms were looked for between nucleotide1,100 upstream from
the start codon (ATG) and the 3untranslated region of theBRCA1 gene using
two data systems: the international HapMap Project (http://hapmap.org) and
Japanese Single-Nucleotide Polymorphisms (http://snp.ims.u-tokyo.ac.jp).
Thirty-five polymorphisms were selected with minor allele frequencies of
more than 10% in Asian ethnic populations. Among these polymorphisms,
four tSNPs were selected using a criterion of more than .9 for the value of the
correlation coefficient (r2). Four tSNPs were chosen with the following prior-
ities: (1) nonsynonymous coding polymorphism; (2) synonymous coding
polymorphism; (3) polymorphism near the start codon; (4) intronic polymor-
phism near an exon; and (5) downstream in order. Finally, IVS12112 (CA;
rs2070833), IVS12-1207 (CT; rs8067269), IVS13-1893A/C (rs8176199), and
S1613G (rs1799966) were identified as tSNPs in this study (Table 1; Appendix
Fig A1, online only).
Genetic Analysis
Genotyping analyses of IVS12112 (CA), IVS12-1207 (CT), and
IVS13-1893 (AC) were performed using the GenomeLab SNPstream Geno-
typing System (ultra-high throughput [UHT]; Beckman Coulter, Fullerton,
CA), according to the manufacturer’s protocol.15 Polymerase chain reaction
(PCR) amplifications were performed in a PTC-225 Peltier Thermal Cycler
(MJ Research, Waltham, MA) using a Taq Gold DNA polymerase. The se-
quences of the PCR and extension primers are listed in Table 1. The S1613G
genotype was analyzed using a single-base primer extension assay employing
the SNaPShot assay kit, according to the manufacturer’s protocol (Applied
Biosystems [ABI], Foster City, CA). The PCR product sequences were ana-
lyzed using electrophoresis on an ABI Prism 3730 DNA analyzer. The results
were analyzed using Gene Mapper software (ABI).
Survival Measurements
The end point of this study was overall survival estimated from the date
of the commencement of chemotherapy. Dates of death were obtained prin-
cipally by contacting the relatives of the patients by phone or mail, or by
reviewing the electronic charts. Seven of the patients could not be contacted,
because they were lost to follow-up after discharge from the hospital; informa-
tion on their survival was collected from the National Statistical Office or the
National Police Agency of Seoul, South Korea.
Statistical Methods
The2 test for heterogeneity was used to compare the distributions of the
clinical variables or genotype frequencies, and the Mann-Whitney U test was
used for continuous variables. Using the Haploview v. 4.0 software package
Table 1. Primers for Amplification and Allele Frequencies of Tagging Polymorphisms
SNP Name rs No. Location Primer Sequence Strand Method Allele Frequency HWE P
S1613G (AG) rs1799966 Exon 16 Forward UHT A:G  0.692:0.308 .9043
Forward AACATACCATCTTCAACCTCTGC
Reverse AATTCTGGCTTCTCCCTGC
Extension RTTGAAAGTTGCAGAATCTGCCCAG
IVS13-1893 (AC) rs8176199 Intron 13 Reverse UHT A:C  0.828:0.172 .1697
Forward TGAATTACAGTCATCAGTGACTTTTT
Reverse GCCTGGCCAAGGCGGAAATAT
Extension ACGCACGTCCACGGTGATTTTATTTAATAAGT
AAAAACAAATAGT
IVS12-1207 (CT) rs8067269 Intron 12 Forward UHT C:T  0.599:0.401 .7241
Forward TTTGGAAAACTCCTTACATACCTAA
Reverse CTGTAAGGATAGTTACTGTTTTTAAAATAATG
Extension GGATGGCGTTCCGTCCTATTTTATCAAATACT
TGGACTTAGCACA
IVS12112 (CA) rs2070833 Intron 12 Reverse SNaPshot C:A  0.724:0.276 .7525
Forward TCCTTTGCATTCAGTAGTATGTATC
Reverse TAAAAGGTAGTATGAGTTCCATCA
Extension GGCTATGATTCGCAATGCTTAGGAGACAATG
AACCACAAACAATT
Abbreviations: SNP, single-nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium.
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(http://www.broad.mit.edu/mpg/haploview/), we determined whether the al-
lele frequencies of the tSNPs were in Hardy-Weinberg equilibrium, and we
estimated the values of Lewontin’s coefficient, D, and r2. Associations be-
tween genotypes or clinical variables and overall survival were estimated using
the Kaplan-Meier method and log-rank testing for univariate analysis. The
hazard ratio, adjusted for potential confounders, and the 95% CI were deter-
mined using the Cox proportional hazards model for multivariate analysis.
The association between haplotype copy number and overall survival was
Table 2. Baseline Patient Characteristics and Copy Numbers of the BRCA1 AACC Haplotype
Variable
All Patients
AACC Haplotype Copy Number
0-1 2
Pearson 2 PNo. % No. % No. %
Total patients 300 265 27
Age, years
Median 63 63 56 .096
Range 28 to 89 28 to 89 41 to 73
Sex
Male 238 79.3 208 89.7 24 10.3 .203
Female 62 20.7 57 95.0 3 5.0
ECOG performance status
0-1 223 74.3 194 89.4 23 10.6 .122
 2 70 23.3 65 95.6 3 4.4
Missing 7 2.3 1 50.0 1 50.0
Histologic cell type
Squamous cell carcinoma 139 46.3 122 89.1 15 10.9 .548
Adenocarcinoma 137 45.7 122 91.7 11 8.3
Mixed 24 8.0 21 95.5 1 4.5
Smoking habit
Never 59 19.7 54 96.4 2 3.6 .103
Ever 241 80.3 211 89.4 25 10.6
Current 174
Former 67
 40 pack years 153 51.0 132 88.6 17 11.4 .594
 40 pack years 88 29.3 79 90.8 8 9.2
Stage
III 141 47.0 126 91.3 12 8.7 .758
IIIA 48
IIIB 93
IV 159 53.0 139 90.3 15 9.7
Tumor response
Complete/partial response 112 37.3 98 91.6 9 8.4 .720
Stable/progressive disease 168 56.0 149 90.3 16 9.7
Missing 20 6.7 18 2
First-line regimen
Platinum/gemcitabine 139 46.3 128 93.4 9 6.6 .128
Platinum/taxane 159 53.0 135 88.2 18 11.8
Paclitaxel 120
Docetaxel 39
Platinum/others 2 0.7 2 100.0 — 0.0
No. of cycles delivered .375
Mean 3.98 3.97 3.70
Standard deviation 1.9 1.9 1.4
Second-line regimen
Total 163 of 300 54.3 145 of 292 49.7 14 of 292 4.8
Platinum doublets 71 of 163 43.6 61 89.7 7 10.3 .438
Single cytotoxic agents 77 of 163 47.2 69 90.8 7 9.2
EGFR TKIs 15 of 163 9.2 15 100.0 0 0.0
Radiation therapy to primary tumor
Total 89 of 300 29.7 77 of 292 26.4 11 of 292 3.8
IIIA 27 of 48 56.3 23 85.2 4 14.8 .369
IIIB 37 of 93 39.8 34 91.9 3 8.1 .99
IV 25 of 159 15.7 20 83.3 4 16.7 .255
Event, deaths 270 90.0 239 90.5 25 9.5 .686
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
Kim et al
5974 © 2008 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
2014 from 128.134.207.85
Information downloaded from jco.ascopubs.org and provided by at SWETS SUBSCRIPTION SERVICE on November 10,
Copyright © 2008 American Society of Clinical Oncology. All rights reserved.
determined using a recessive model. All analyses were performed using the SAS
software package (version 9.1.3; SAS Institute, Cary, NC).
RESULTS
Patients and Treatment
Table 2 provides the demographic and clinical information for
the 300 patients in this study. Their median age was 63 years (range, 28
to 89 years), and 238 of the patients (79%) were men. Most of the
patients (223 of 300, 74%) had an Eastern Cooperative Oncology
Group (ECOG) performance status of 1 or better. At the time of
diagnosis, 16% of patients had stage IIIA disease, 31% had stage IIIB
disease, and 53% had stage IV disease. With regard to histologic cell
type, 46.3% of the patients had squamous cell carcinomas and 45.7%
had adenocarcinomas. As a first-line regimen, 159 patients (53%)
received taxane doublets, and 139 patients (46%) received gemcitab-
ine doublets. Among 163 (54%) patients who received second-line
chemotherapy, platinum doublets and single-agent chemotherapy
with a cytotoxic agent accounted for 91%. Radiation therapy to the
primary tumor was administered to 89 patients (30%). We observed
events (deaths) in 270 of the 300 patients (90%).
Genotypes and Allele Frequencies of the Tagging
Polymorphisms of BRCA1
Three of the tSNPs were located in introns; the other tSNP, in
exon 16, was a nonsynonymous polymorphism causing an amino acid
change (serine to glycine; Table 1). A Hardy-Weinberg equilibrium
was observed for all tSNPs. The frequencies of the variant alleles were
as follows: 30% for S1613G, 17% for IVS13-1893 (AC), 40% for
IVS12-1207 (CT), and 27% for IVS12112 (CA). No associa-
tions were demonstrated between each tSNP and sex, ECOG perfor-
mance status (0 to 1 v  2), histologic cell type (squamous cell
carcinoma v adenocarcinoma), smoking habit (never smoker v ever
smoker), stage (III v IV), tumor response (complete or partial remis-
sion v stable disease or progression), first-line regimen (gemcitabine v
taxanes), second-line treatment (yes v no), or sequential radiation
therapy (yes v no; data not shown).
Linkage Disequilibrium and BRCA1 Haplotype
The linkage disequilibrium (LD) values for S1613G, IVS13-1893
(AC), IVS12-1207 (CT), and IVS12112 (CA) are shown in
Appendix Table A1 (online only). High LDs were observed for all four
tSNPs with D values of 1, but the r2 values were intermediate (range,
.08 to .664). Using the Haploview v. 4.0 software package, we con-
structed haplotypes ofBRCA1 in the following order: S1613G, IVS13-
1893 (AC), IVS12-1207 (CT), and IVS12112 (CA); we then
identified six haplotypes (Appendix Table A2, online only). The five
common haplotypes were AACC, AACA, GCTC, GATC, and AATC,
which together accounted for 99.9% of all haplotypes. The AACC
haplotype was most commonly observed with 32.1% of frequency.
Association of Tagging Polymorphisms With
Overall Survival
The median survival time (MST) of the 300 patients was 13.0
months. No associations were demonstrated between the tSNPs and
overall survival of the patients. However, patients with the wild-type
allele among the four tSNPs tended to survive for shorter periods than
patients with one or two variant-type alleles, although this trend was
not statistically significant (Table 3).
Association of Clinical Variables or Haplotypes of
BRCA1 With Overall Survival
When the association between the clinical variables and overall
survival of patients was analyzed, weight loss ( 5%), ECOG perfor-
mance status ( 2), stage (IV), second-line treatment (no), or radia-
tion therapy (no) had significant association with shorter survival
according to the log-rank tests and Cox proportional hazards model
(Table 4). The other clinical variables we examined (sex, smoking
habit, histologic cell type, and first-line regimen) were not prognostic
factors in the context of this study.
We classified the 292 patients into two groups according to the
copy number of the allele in each BRCA1 haplotype: one group had
zero or one copy and the other group had two copies. We analyzed the
two groups statistically using a recessive model, and we evaluated the
association between copy numbers of the five BRCA1 haplotypes and
Table 3. Association Between Tagging Polymorphisms of BRCA1 and Overall Survival
Variable
Patients
MST (months) 95% CI Hazard Ratio 95% CI P No. %
S1613G (AG)
Ser/Ser 140 47.5 12.7 10.5 to 14.9 1.0 Reference
Ser/GlyGly/Gly 155 52.5 14.4 11.6 to 17.2 0.781 0.604 to 1.011 .061
IVS13-1893 (AC)
AA 201 67.2 12.7 10.8 to 14.6 1.0 Reference
ACCC 98 32.8 14.6 11.4 to 17.9 0.892 0.632 to 1.087 .174
IVS12-1207 (CT)
CC 109 36.5 12.9 10.6 to 15.2 1.0 Reference
CTTT 190 63.5 13.0 10.5 to 15.5 0.850 0.652 to 1.108 .230
IVS12112 (CA)
CC 154 51.9 12.8 10.6 to 15.0 1.0 Reference
CAAA 143 48.1 13.7 10.8 to 16.5 0.978 0.757 to 1.265 .869
Abbreviations: MST, median survival time; Ser, serine; Gly, glycine.
Estimated from Cox proportional hazards model, adjusted for body weight loss, Eastern Cooperative Oncology Group performance status, stage, second-line
treatment, and radiation therapy.
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overall survival. We could not demonstrate an association between
any of the four less common haplotypes (AACA, GCTC, GATC, and
AATC) and survival time (data not shown), but patients with two
copies of AACC, the wild-type haplotype, showed significantly
shorter survival than patients with zero or one copy (MST, 8.5 v
14.6 months; log-rank P .0066; Table 4; Fig 1). After adjusting for
the confounding variables identified by univariate analysis, the Cox
model showed that patients with two copies had a two-fold higher risk
of death than patients with zero or one copy of the AACC haplotype
(hazard ratio [HR] 2.097; 95% CI, 1.339 to 3.284). No associations
were observed between the two groups by AACC haplotype or clinical
variables (Table 1).
AACC Haplotype of BRCA1 and Overall Survival:
Subgroup Analysis
We analyzed the effect of the copy number of the wild-type
haplotype AACC on survival by cell type, smoking habit, sex, and
chemotherapy regimen (Fig 2). In patients with squamous cell carci-
nomas, the MST of patients with the two copies was 6.8 months, less
than half that of the MST of patients with zero or one copy (log-rank
P 3.6 105). In the Cox model, patients with two copies showed
an increased risk of death (HR  3.20; 95% CI, 1.74 to 5.97). In
contrast, no association was demonstrated in patients with adenocar-
cinoma (log-rank P .6774; HR  0.919; 95% CI, 0.429 to 1.968).
When the effect of copy number was analyzed according to smoking
habit and sex, smokers or males with the two copies displayed signif-
icantly shorter survival (log-rank P for smokers .0016; HR 2.01;
Table 4. Association Between Copy Number of BRCA1 AACC Haplotype or Clinical Variables and Overall Survival
Variable
Univariate Multivariate
MST (months) 95% CI Log-Rank P Hazard Ratio 95% CI P
AACC
Copy number, 0-1 14.57 12.40 to 16.73 .0066 1.0 Reference
Copy number, 2 8.47 6.94 to 9.99 2.097 1.339 to 3.284 .001
Weight loss, %
 5 15.47 14.12 to 16.81 .0242 1.0 Reference
 5 10.83 9.14 to 12.53 1.351 1.050 to 1.739 .020
ECOG performance status
0-1 14.57 12.40 to 16.73 .0010 1.0 Reference
 2 10.00 7.68 to 12.32 1.545 1.154 to 2.068 .003
Stage
IIIA/IIIB 14.67 11.90 to 17.43 .0125 1.0 Reference
IV 11.60 9.32 to 13.88 1.257 0.958 to 1.649 .098
Second-line treatment
Yes 15.77 13.64 to 17.89 .0038 1.0 Reference
No 10.00 8.14 to 11.86 1.502 1.159 to 1.947 .002
Radiation therapy to primary tumor
Yes 16.63 11.42 to 21.84 .0005 1.0 Reference
No 11.60 10.18 to 13.02 1.720 1.274 to 2.321 .000
Sex
Female 15.23 12.21 to 18.26 .4576
Male 12.23 10.45 to 14.02
Smoking habit
Never 15.23 11.86 to 18.60 .2287
Ever 12.33 10.53 to 14.14
Histologic cell type
Squamous cell carcinoma 14.17 11.39 to 16.94 .1847
Adenocarcinoma 13.30 11.11 to 15.49
First-line treatment
Platinum/gemcitabine 11.90 9.59 to 14.21 .1682
Platinum/taxanes (P,D) 13.67 11.36 to 15.97
Abbreviations: MST, median survival time; ECOG, Eastern Cooperative Oncology Group; P,D, paclitaxel/docetaxel.
Estimated from Cox proportional hazards model, adjusted for body weight loss, ECOG performance status, stage, second-line treatment, and radiation therapy.
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95% CI, 1.248 to 3.240; log-rankP for males .0070; HR1.96; 95%
CI, 1.217 to 3.187). However, no association was observed among
never smokers or females (log-rank P for never smokers  .5578;
HR 0.994; 95% CI, 0.201 to 4.926; log-rank P for females .8807;
HR 1.586; 95% CI, 0.355 to 7.089). With respect to chemotherapy
regimen, the two copies showed significantly shorter survival after
taxanes/cisplatin, but this effect was not present in gemcitabine-/
cisplatin-treated patients (log-rank P for taxanes/cisplatin  .0082;
HR  2.053; 95% CI, 1.123 to 3.752; log-rank P for gemcitabine/
cisplatin .3009; HR 1.606; 95% CI, 0.763 to 3.382).
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0 or 1 135 15.2 M 12.5 to 17.9
2 18 6.8 M 2.7 to 10.8
Log-rank P = .0082
Fig 2. Overall survival of subgroups according to AACC haplotype of BRCA1. (A) Squamous cell carcinoma, (B) adenocarcinoma, (C) ever smokers, (D) never
smokers, (E) ever-smokers  40 pack years, (F) ever smokers  40 pack years, (G) males, (H) females, (I) taxanes/cisplatin, and (J) gemcitabine/cisplatin. MST,
median survival time.
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DISCUSSION
We demonstrated the importance of BRCA1 haplotype in predicting
the prognosis of lung cancer patients treated with platinum-based
chemotherapy, especially those with squamous cell carcinomas.
BRCA1crucially participates in the DNA repair mechanism10,11 and in
regulating mitotic spindle assembly.12,13 Accordingly, some evidence
supports the idea that BRCA1 mRNA or protein levels could be bi-
omarkers indicating the response to chemotherapeutic agents in can-
cers of the lung14 and ovary.16,17 A lower expression level is predictive
of better survival in treatment with DNA-damaging agents, such as
platinum, whereas a higher level can indicate a benefit from anticancer
drugs that act on tubulin, such as taxanes (paclitaxel or docetaxel).
Most previous studies looking for associations between germ-
line variations in BRCA1 and survival have investigated cancers in
breast,18 ovary,19-21 or other tissue,22 in which the founder mutations
or unclassified variants (UVs) ofBRCA1were evaluated. Chetrit et al21
recently reported longer survival in ovarian cancers patients with
founder mutations, even after adjustment for some confounding fac-
tors. In a report by Majdak et al,20 UVs showed no prognostic signifi-
cance. However, Garcia et al23 demonstrated different clinical features
among patients with UVs, a finding that warrants a further study with
a large number of patients to confirm the relevance of UVs.
In contrast, existing studies have rarely investigated associations
between BRCA1 gene polymorphisms, or their functional signifi-
cance, with survival of cancer patients. To the best of our knowledge,
this study is the first to demonstrate the effects of germ-line polymor-
phisms on the survival of lung cancer patients.
Regarding possible methodologic issues with this study, only
SNPs with a minor allele frequency of more than 10% in the Asian
ethnic group were chosen from the two databases to enhance the
clinical applicability of the association study. Then, we selected four
tSNPs believed to represent corresponding SNPs with 90% probability
(Table 1; Fig A1).
In this study, patients with the wild-type alleles of each BRCA1
tSNP tended to display shorter survival periods than patients harbor-
ing one or two variant-type alleles, although the differences were not
statistically significant (Table 4). Furthermore, the effect on survival
was most evident when the wild-type alleles were combined to con-
struct the AACC wild-type haplotype. This haplotype occurred with
the highest frequency in our population, accounting for 32% of the
patients. Patients with two copies of the wild-type haplotype AACC
showed significantly shorter survival than patients with zero or one
copy (Fig 1). To explain these results, we hypothesize that the two
copies may convey proficient BRCA1 function, which hampers the
efficacy of DNA-damaging drugs.
In the subgroup analysis, the effect of the two copies depended
on cell type, as well as on some clinical variables (sex, smoking
habit, and chemotherapy regimen). Squamous cell carcinoma is
more common among smokers than adenocarcinoma.24 Ever
smokers have more proficient DNA repair capacity than never
smokers;25-27 therefore, in estimating the effect of a polymorphism,
smoking habit is an important determinant in terms of the gene
environment interaction.25-29 So far, no clear evidence has suggested
that smoking modulates the effects of BRCA1 polymorphisms or
haplotypes. We assume that the DNA repair capacity can be synergis-
tically enhanced in patients carrying the two copies and with certain
phenotypes (squamous cell carcinomas, males, and heavy smokers),
in whom the benefit from platinum may decrease. These are common
phenotypes among lung cancer patients in South Korea, and in other
countries that still have a high prevalence of smoking. This could
detract from the benefit of currently available biologic agents.2-4 Inter-
estingly, we observed significantly shorter survival in patients with the
two copies who were treated with taxanes/cisplatin, but not in those
treated with gemcitabine. We therefore assume that synergism be-
tween taxanes and cisplatin is impaired by efficient BRCA1 function,
whereas gemcitabine is not affected.14 The results of this study suggest
that an alternative option, such as a nonplatinum combination or a
nontaxane regimen could be considered in when treating NSCLC
patients with the two copies and the phenotypes associated with de-
creased effectiveness.
There have been publications on genes involving DNA repair.
Therefore, gene-gene interactions with BRCA1 may synergistically
potentiate prognostic significance and generate a more robust model
for clinicians to utilize as a guide in patient treatment assignment.
However, several concerns may hinder developing a useful model.
Genetic differences among ethnic groups could affect the benefit from
this approach; for example, even though ERCC2 (Lys751Gln and
Asp231Asn) reportedly has a prognostic role in white NSCLC pa-
tients,7 the frequency of Korean patients homozygous for this variant
is extremely low.8,30 Another concern is confounding factors poten-
tially affecting a gene’s effect on survival (eg, the effect of DNA repair
gene SNPs on survival varies with is effective in stage III, but not in
stage IV) or smoking habit.7,28 Finally, in two genes’ interaction anal-
ysis between BRCA1 and ERCC1 Asn118Asn, a prognostic marker in
our cohort,8,28 only 4.4% (13 of 291) of the patients carried both the
two copies ofBRCA1 andERCC1Asn/Asp or Asn/Asn. The death risk
was indeed higher for these patients than in patients with the two
copies of BRCA1 alone (log-rank P for combined effect  .0016;
HR 2.611; 95% CI, 1.400 to 4.870 after adjustment for sex, smoking
habit, histologic cell type, stage, performance status, and weight loss,
unpublished data). However, the size of the stratum holding prognos-
tic significance decreased more than 50%. Although two or more
genes’ interaction analysis among genes involved in DNA repair may
be sound and more informative, how many patients are beneficial
from the approach is another important clinical issue or concern.
The results of this study must be interpreted with some caution.
First, this study may potentially be limited by its retrospective nature.
However, a total of 300 patients were treated in a single institution
with platinum-based chemotherapy as the first-line treatment, with
clinical information obtained prospectively. We believe that this re-
duced bias from possible confounding factors. Second, the question of
whether the copy number of the wild-type haplotype AACC differen-
tially affects BRCA1 function remains unanswered, and must be ad-
dressed in a future study. Third, the effect of the two copies among
subgroups may be limited by small numbers of patients in each stra-
tum, particularly in never smokers.
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